Increased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

PLoS One

Fei Yu¹  Yang Han¹  Xueyu Yuan¹  Haidong Cai¹  Li Cai¹  Jin Liu¹  Suyun Fang¹  Chengyou Jia¹  Zhongwei Lv¹  Yushui Ma¹  Yu Sun¹  Da Fu¹  Huiqiong Yang¹  Dan Li¹  Xiaoming Zhong²  Ming Li³  Ruting Xie⁴  Qing Wei⁴  Xianling Cong⁵ 

[1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai, China

[2]Department of Radiology, Jiangxi Provincial Tumor Hospital, Nanchang, China

[3]Department of Respiratory Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai, China

[4]Department of pathology, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai, China

[5]Tissue Bank, China-Japan Union Hospital, Jilin University, Changchun, China

关键词: Non-small cell lung cancer;    Cancer treatment;    Cancer chemotherapy;    Lung and intrathoracic tumors;    Metastasis;    Secondary lung tumors;    Chemotherapy;    Prognosis;   

DOI  :  10.1371/journal.pone.0134682

学科分类：医学（综合）

来源: Public Library of Science

【 摘 要 】

To investigate the prognostic significance of TGFβR2 expression and chemotherapy in Chinese non-small cell lung cancer (NSCLC) patients, TGFβR2 expression NSCLC was analyzed in silico using the Oncomine database, and subsequently analyzed with quantitative RT-PCR in 308 NSCLC biopsies, 42 of which were paired with adjacent non-neoplastic tissues. Our results show that TGFβR2 expression was also increased in NSCLC biopsies relative to normal tissue samples and correlated with poor prognosis. TGFβR2 expression was also significantly correlated with other clinical parameters such as tumor differentiation, invasion of lung membrane, and chemotherapy. Moreover, overall survival (OS) and disease free survival (DFS) was increased in patients with low TGFβR2 expressing NSCLC and who had undergone chemotherapy. Thus, high expression of TGFβR2 is a significant risk factor for decreased OS and DFS in NSCLC patients. Thus, TGFβR2 is a potential prognostic tumor biomarker for chemotherapy.

【 授权许可】

CC BY